10x Genomics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M | $490.5M |
| Cost of revenue | $198.9M | $196.3M | $209.4M | $120.4M | $74.1M |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M |
| Selling, general & administrative | $316.1M | $344.3M | $343.3M | $298.3M | $257.6M |
| Research and development | $238.6M | $264.7M | $270.3M | $265.7M | $211.8M |
| Operating expenses | $504.9M | $609.0M | $674.6M | $564.0M | $468.7M |
| Operating income | -$61.0M | -$194.6M | -$265.3M | -$167.9M | -$52.3M |
| Interest expense | $0 | $4,000 | $33,000 | $476,000 | $866,000 |
| Pretax income | -$39.9M | -$177.7M | -$248.8M | -$162.0M | -$53.7M |
| Income tax expense | $3.6M | $4.9M | $6.3M | $4.0M | $4.5M |
| Net income | -$43.5M | -$182.6M | -$255.1M | -$166.0M | -$58.2M |
| Balance Sheet | |||||
| Cash and equivalents | — | $344.1M | $359.3M | $219.7M | $587.4M |
| Current assets | $684.5M | $584.4M | $596.0M | $635.0M | $747.6M |
| Total assets | $1.0B | $918.6M | $965.1M | $1.0B | $1.0B |
| Current liabilities | $153.5M | $117.6M | $127.2M | $131.0M | $110.4M |
| Total liabilities | $245.0M | $208.5M | $224.1M | $223.2M | $201.3M |
| Stockholders' equity | $796.3M | $710.1M | $741.0M | $805.7M | $817.6M |
| Cash Flow Statement | |||||
| Cash from operations | $136.1M | $6.7M | -$15.2M | -$33.6M | -$21.4M |
| Depreciation and amortization | $36.2M | $35.9M | $35.5M | $25.4M | $21.1M |
| Stock-based compensation | $109.1M | $140.7M | $166.9M | $136.8M | $96.0M |
| Capital expenditure | $5.9M | $12.4M | $48.6M | $131.7M | $101.3M |
| Free cash flow | $130.1M | -$5.7M | -$63.8M | -$165.3M | -$122.7M |
| Impairments | $2.1M | $3.1M | $9.8M | $0 | $0 |
Shares outstanding 127.0M · Free float 84.2%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.